Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria; email:
Annu Rev Med. 2016;67:1-10. doi: 10.1146/annurev-med-053014-103600. Epub 2015 Aug 28.
Randomized trials have studied bisphosphonates in the adjuvant setting of early breast cancer to investigate their ability to prevent treatment-induced bone loss. Trial results have also suggested their potential to prevent disease recurrence and metastases. These trials are summarized in this review. A recent patient-level meta-analysis by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) finds convincing evidence that adjuvant antiresorptive treatments provide persistent benefits to breast cancer patients in low-estrogen situations and should be considered an important part of the treatment algorithm.
随机临床试验已经研究了双膦酸盐在早期乳腺癌的辅助治疗中，以研究它们预防治疗引起的骨丢失的能力。试验结果还表明，它们有可能预防疾病复发和转移。本综述总结了这些试验。早期乳腺癌试验者协作组（EBCTCG）最近进行的一项基于患者的荟萃分析发现，令人信服的证据表明，辅助抗吸收治疗为低雌激素情况下的乳腺癌患者提供了持续的益处，应被视为治疗方案的重要组成部分。
